site news

ZIRCON-X Study Changes Renal Cancer Treatment

9 January 2026

As reported by online publication 'Uro Today GU ONC Today,' a presentation by Dr. Brian Shuch during the 2025 SUO Kidney Session revealed significant changes when diagnosing clear cell renal cell carcinoma (ccRCC), when using 89Zr-girentuximab PET/CT versus conventional imaging. Nearly 300-patients data were compared in the ZIRCON-X trial, and findings revealed that almost half had changes in diagnosis following conventional imaging having a blind follow-up PET/CT imaging using 89Zr-girentuximab.

Here is the link to read all the patient details from the 'Uro Today GU ONC Today' report: https://www.urotoday.com/conference-highlights/suo-2025/suo-2025-kidney-cancer/165246-suo-2025-zircon-x-impact-of-89zr-girentuximab-pet-ct-versus-conventional-imaging-on-clinical-decision-making-in-patients-with-indeterminate-renal-masses.html

Here is the link to a video interview of Dr. Shuch produced by 'Uro Today GU ONC Today' with Dr. Pedro Barata: https://www.urotoday.com/video-lectures/managing-renal-masses-in-renal-cell-carcinoma/video/5240-zircon-x-how-caix-pet-imaging-influences-surgery-biopsy-and-treatment-strategy-in-indeterminate-renal-masses-brian-shuch.html